Impact

The EMAPs-Cardio project will contribute to the following impacts:

Verifiable progress in the application of Organ-on-Chip (OoC) technologies for in vitro research
Reduction of the number of clinical trials
Higher drug approval rate
Elimination of animal testing for cardiovascular drug screening
Lowering of barriers for application of OoC technology
Improved competitiveness and attractiveness of the European biomedical and healthcare sector
Increased investment to cardiovascular drug research and development
Strengthened collaboration between European SMEs and academia